Faron Pharmaceuticals Oy
FARN.LDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
FP-1305 (bexmarilimab)
Cancer
Bexmarilimab
Acute Myeloid Leukemia
Interferon Beta
Acute Lung Injury
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FP-1305 (bexmarilimab) | Phase 2 | Cancer | - | - |
Bexmarilimab | Phase 2 | Acute Myeloid Leukemia | - | - |
Interferon Beta | Phase 2 | Acute Lung Injury | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Faron Pharmaceuticals Oy's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Faron Pharmaceuticals Oy's (FARN.L) pipeline across Phase 2. Its lead program is FP-1305 (bexmarilimab) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Faron Pharmaceuticals Oy's next FDA catalyst?→
Faron Pharmaceuticals Oy's (FARN.L) next tracked catalyst is a Phase 2 expected March 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track FARN.L biotech catalysts?→
Add FARN.L to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Faron Pharmaceuticals Oy's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.